Header Logo

Connection

STEPHEN HAHN to Aged

Back to Details
This is a "connection" page, showing publications STEPHEN HAHN has written about Aged.
STEPHEN HAHN
Connection Strength
0.481
Aged
  1. Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer. Lung Cancer. 2018 07; 121:30-36.
    View in: PubMed
    Score: 0.027
  2. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: pilot study results. Cancer. 2015 Jan 01; 121(1):139-49.
    View in: PubMed
    Score: 0.021
  3. Principles and reality of proton therapy treatment allocation. Int J Radiat Oncol Biol Phys. 2014 Jul 01; 89(3):499-508.
    View in: PubMed
    Score: 0.020
  4. A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response. J Thorac Oncol. 2012 Apr; 7(4):709-15.
    View in: PubMed
    Score: 0.018
  5. Combined modality therapy in the elderly population. Curr Treat Options Oncol. 2009 Aug; 10(3-4):195-204.
    View in: PubMed
    Score: 0.014
  6. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg Med. 2006 Jun; 38(5):427-34.
    View in: PubMed
    Score: 0.012
  7. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol. 2006; 25(1-2):373-87.
    View in: PubMed
    Score: 0.011
  8. A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin Cancer Res. 2004 Oct 01; 10(19):6411-7.
    View in: PubMed
    Score: 0.010
  9. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5447-54.
    View in: PubMed
    Score: 0.010
  10. Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J Clin Oncol. 2004 Jun 01; 22(11):2192-201.
    View in: PubMed
    Score: 0.010
  11. Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis. Int J Oncol. 2004 Mar; 24(3):711-7.
    View in: PubMed
    Score: 0.010
  12. Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy. Photochem Photobiol. 2003 Jul; 78(1):75-81.
    View in: PubMed
    Score: 0.010
  13. A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg. 2003 Mar; 75(3):952-9.
    View in: PubMed
    Score: 0.009
  14. A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res. 2002 May; 8(5):1065-72.
    View in: PubMed
    Score: 0.009
  15. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol. 2001 Mar 01; 19(5):1344-9.
    View in: PubMed
    Score: 0.008
  16. Toxicity of photodynamic therapy after combined external beam radiotherapy and intraluminal brachytherapy for carcinoma of the upper aerodigestive tract. Lasers Surg Med. 2001; 28(3):278-81.
    View in: PubMed
    Score: 0.008
  17. Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity. J Surg Oncol. 2020 Oct; 122(5):877-883.
    View in: PubMed
    Score: 0.008
  18. Circulating Tumor Cells Are Associated with Recurrent Disease in Patients with Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy. Clin Cancer Res. 2020 05 15; 26(10):2372-2380.
    View in: PubMed
    Score: 0.008
  19. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
    View in: PubMed
    Score: 0.007
  20. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol. 2019 06 01; 5(6):872-878.
    View in: PubMed
    Score: 0.007
  21. Early Detection of Recurrence in Patients With Locally Advanced Non-Small-Cell Lung Cancer via Circulating Tumor Cell Analysis. Clin Lung Cancer. 2019 09; 20(5):384-390.e2.
    View in: PubMed
    Score: 0.007
  22. Gender, Professional Experiences, and Personal Characteristics of Academic Radiation Oncology Chairs: Data to Inform the Pipeline for the 21st Century. Int J Radiat Oncol Biol Phys. 2019 08 01; 104(5):979-986.
    View in: PubMed
    Score: 0.007
  23. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Radiother Oncol. 2019 03; 132:55-62.
    View in: PubMed
    Score: 0.007
  24. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br J Cancer. 2018 11; 119(10):1200-1207.
    View in: PubMed
    Score: 0.007
  25. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location. Clin Lung Cancer. 2019 01; 20(1):e63-e71.
    View in: PubMed
    Score: 0.007
  26. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw Open. 2018 08 03; 1(4):e181390.
    View in: PubMed
    Score: 0.007
  27. Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer. JAMA Oncol. 2018 08 01; 4(8):e174504.
    View in: PubMed
    Score: 0.007
  28. Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):536-542.
    View in: PubMed
    Score: 0.007
  29. Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer. Cancer Med. 2018 06; 7(6):2247-2255.
    View in: PubMed
    Score: 0.007
  30. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 06 20; 36(18):1813-1822.
    View in: PubMed
    Score: 0.007
  31. Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. Radiother Oncol. 2017 11; 125(2):325-330.
    View in: PubMed
    Score: 0.006
  32. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032.
    View in: PubMed
    Score: 0.006
  33. Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Oncol. 2018 Jan - Feb; 8(1):58-65.
    View in: PubMed
    Score: 0.006
  34. Polymorphisms in BMP2/BMP4, with estimates of mean lung dose, predict radiation pneumonitis among patients receiving definitive radiotherapy for non-small cell lung cancer. Oncotarget. 2017 Jun 27; 8(26):43080-43090.
    View in: PubMed
    Score: 0.006
  35. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 2017 Aug 15; 123(16):3031-3039.
    View in: PubMed
    Score: 0.006
  36. Long-Term Outcomes of Salvage Stereotactic Ablative?Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol. 2017 06; 12(6):983-992.
    View in: PubMed
    Score: 0.006
  37. Radiation Therapy is Independently Associated with Worse Survival After R0-Resection for Stage I-II Non-small Cell Lung Cancer: An Analysis of the National Cancer Data Base. Ann Surg Oncol. 2017 May; 24(5):1419-1427.
    View in: PubMed
    Score: 0.006
  38. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol. 2017 02; 122(2):274-280.
    View in: PubMed
    Score: 0.006
  39. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):900-907.
    View in: PubMed
    Score: 0.006
  40. Is there a role for salvage radiotherapy in locally advanced breast cancer refractory to neoadjuvant chemotherapy? Breast. 2017 Feb; 31:192-196.
    View in: PubMed
    Score: 0.006
  41. Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years. Ann Thorac Surg. 2017 Mar; 103(3):912-919.
    View in: PubMed
    Score: 0.006
  42. Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 02; 12(2):281-292.
    View in: PubMed
    Score: 0.006
  43. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection. J Surg Oncol. 2016 Jul; 114(1):65-9.
    View in: PubMed
    Score: 0.006
  44. A novel approach for the detection and genetic analysis of live melanoma circulating tumor cells. PLoS One. 2015; 10(3):e0123376.
    View in: PubMed
    Score: 0.005
  45. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Cancer. 2015 Apr 01; 121(7):1118-27.
    View in: PubMed
    Score: 0.005
  46. Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study. Cancer Biol Ther. 2014 Jun 01; 15(6):683-7.
    View in: PubMed
    Score: 0.005
  47. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res. 2014 Apr 15; 74(8):2152-9.
    View in: PubMed
    Score: 0.005
  48. A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme. J Neurooncol. 2014 Jan; 116(2):365-372.
    View in: PubMed
    Score: 0.005
  49. Burnout in United States academic chairs of radiation oncology programs. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):363-8.
    View in: PubMed
    Score: 0.005
  50. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. Cancer. 2013 Sep 01; 119(17):3123-32.
    View in: PubMed
    Score: 0.005
  51. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013 May 01; 119(9):1729-35.
    View in: PubMed
    Score: 0.005
  52. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2012 May; 93(5):1658-65; discussion 1665-7.
    View in: PubMed
    Score: 0.004
  53. Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):e13-9.
    View in: PubMed
    Score: 0.004
  54. Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: an analysis of the surveillance, epidemiology, and end results registry. Ann Surg Oncol. 2012 Apr; 19(4):1316-23.
    View in: PubMed
    Score: 0.004
  55. Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma. Ann Thorac Surg. 2011 Jun; 91(6):1738-45.
    View in: PubMed
    Score: 0.004
  56. Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma. Cancer Biol Ther. 2010 Sep 01; 10(5):425-9.
    View in: PubMed
    Score: 0.004
  57. Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors. Radiat Res. 2008 Dec; 170(6):677-90.
    View in: PubMed
    Score: 0.003
  58. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int J Radiat Oncol Biol Phys. 2007 Nov 15; 69(4):1024-31.
    View in: PubMed
    Score: 0.003
  59. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007 Nov 01; 69(3):646-55.
    View in: PubMed
    Score: 0.003
  60. EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):922-7.
    View in: PubMed
    Score: 0.003
  61. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res. 2004 Dec 15; 10(24):8177-84.
    View in: PubMed
    Score: 0.003
  62. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res. 2004 Mar 01; 64(5):1886-92.
    View in: PubMed
    Score: 0.003
  63. Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung. 2004; 182(3):151-62.
    View in: PubMed
    Score: 0.002
  64. Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy. Cancer Chemother Pharmacol. 2003 Sep; 52(3):217-22.
    View in: PubMed
    Score: 0.002
  65. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. Clin Cancer Res. 2002 Aug; 8(8):2524-9.
    View in: PubMed
    Score: 0.002
  66. Vascularity and uptake of photosensitizer in small human tumor nodules: implications for intraperitoneal photodynamic therapy. Clin Cancer Res. 2001 Dec; 7(12):3904-11.
    View in: PubMed
    Score: 0.002
  67. Hypoxia in human intraperitoneal and extremity sarcomas. Int J Radiat Oncol Biol Phys. 2001 Feb 01; 49(2):587-96.
    View in: PubMed
    Score: 0.002
  68. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res. 2000 Apr 01; 60(7):2018-24.
    View in: PubMed
    Score: 0.002
  69. Non-small cell lung cancer: prognostic factors in patients treated with surgery and postoperative radiation therapy. Radiology. 1999 Dec; 213(3):845-52.
    View in: PubMed
    Score: 0.002
  70. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J Clin Oncol. 1998 Feb; 16(2):635-41.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.